Home » Stocks » Organovo Holdings

Organovo Holdings, Inc. (ONVO)

Stock Price: $10.81 USD 2.49 (29.93%)
Updated Oct 21, 2020 4:00 PM EDT - Market closed
After-hours: $10.90 +0.09 (0.83%) Oct 21, 7:57 PM

Stock Price Chart

Key Info

Market Cap 70.60M
Revenue (ttm) 1.53M
Net Income (ttm) -15.16M
Shares Out 6.53M
EPS (ttm) -2.32
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 21, 2020
Last Price $10.81
Previous Close $8.32
Change ($) 2.49
Change (%) 29.93%
Day's Open 8.25
Day's Range 8.25 - 11.39
Day's Volume 1,326,253
52-Week Range 3.87 - 18.60

More Stats

Market Cap 70.60M
Enterprise Value 45.81M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 6.53M
Float 6.40M
EPS (basic) -2.40
EPS (diluted) -2.32
FCF / Share -1.65
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 145,381
Short Ratio 1.36
Short % of Float 2.27%
Beta 0.95
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 46.20
PB Ratio 2.55
Revenue 1.53M
Operating Income -17.74M
Net Income -15.16M
Free Cash Flow -10.77M
Net Cash 24.79M
Net Cash / Share 3.80
Gross Margin -223.56%
Operating Margin -1,160.99%
Profit Margin -991.90%
FCF Margin -704.78%
ROA -21.74%
ROE -49.75%
ROIC -930.10%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$30.00*
Low
30.0
Current: $10.81
High
30.0
Target: 30.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue2.203.094.604.231.480.570.381.200.970.60
Revenue Growth-28.96%-32.85%8.82%185.23%159.72%50.66%-68.34%23.53%60.7%-
Gross Profit1.872.613.573.271.480.570.381.200.850.60
Operating Income-21.48-27.27-35.27-38.58-38.64-30.30-20.65-9.32-2.31-1.18
Net Income-18.71-26.64-34.80-38.45-38.58-30.08-25.85-43.55-4.38-1.34
Shares Outstanding6.485.775.364.894.503.983.662.161.150.73
Earnings Per Share-2.80-4.60-6.40-7.80-8.60-7.60-7.00-20.20-3.80-1.80
Operating Cash Flow-14.88-20.38-28.86-29.19-29.37-19.60-15.56-9.69-1.91-0.82
Capital Expenditures0.75-0.08-0.22-1.34-2.10-1.52-0.28-0.36-0.05-0.05
Free Cash Flow-14.14-20.45-29.08-30.53-31.47-21.12-15.84-10.05-1.96-0.87
Cash & Equivalents27.3636.5643.8562.8862.1750.2248.2514.910.34-
Total Debt-----0.010.020.030.70-
Net Cash / Debt27.3636.5643.8562.8862.1750.2248.2314.88-0.36-
Assets28.4440.6249.8369.1867.5853.4950.1916.751.41-
Liabilities1.814.335.246.825.404.791.9022.053.24-
Book Value26.6336.3044.5962.3662.1848.7048.28-5.30-1.84-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Organovo Holdings, Inc.
Country United States
Employees 6
CEO Keith Murphy

Stock Information

Ticker Symbol ONVO
Stock Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Unique Identifier NASDAQ: ONVO

Description

Organovo Holdings, a biotechnology company, develops bioprinted human tissues based on its 3D human tissue platform technology that emulate human biology and diseases. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing in vivo liver tissues to treat end-stage liver, life-threatening, and orphan diseases; and NovoTissues liver product using cells from a liver donor and cells from an umbilical cord donor. The company was founded in 2007 and is headquartered in Solana Beach, California.